CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 54514-54851 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"Methods: AQLQ data (n=948) from two randomized, double-blind, placebo-controlled clinical trials were pooled to assess underlying variability in the mean scores and to identify key drivers of ARQL treatment-effect differences (Juniper-Asthma Quality of Life Questionnaire (AQLQ)) between omalizumab and placebo (active control) patients.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T87828","span":{"begin":0,"end":337},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T87828","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T43","span":{"begin":0,"end":337},"obj":"Sentence"}],"attributes":[{"subj":"T43","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T479","span":{"begin":235,"end":241},"obj":"Disease"}],"attributes":[{"id":"A479","pred":"mondo_id","subj":"T479","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"subj":"T479","pred":"source","obj":"CORD-19-PD-MONDO"}]},{"project":"CORD-19-PD-HP","denotations":[{"id":"T250","span":{"begin":235,"end":241},"obj":"Phenotype"}],"attributes":[{"id":"A250","pred":"hp_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"subj":"T250","pred":"source","obj":"CORD-19-PD-HP"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93ecaa","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ec9395"},{"id":"CORD-19-PD-MONDO","color":"#93afec"},{"id":"CORD-19-PD-HP","color":"#c9ec93"}]}]}}